The overall purpose of the Clinical Management and Trials Core of the UAB/UMN SPORE in Pancreatic Cancer is to provide a coordinated infrastructure and expertise at both sites to support SPORE investigators in translation of their mature basic science ideas into clinical protocols. This will be accomplished through the following speciflc aims: (1) To provide a comprehensive, multi-disciplinary, patient care clinical pathway for all patients with pancreatic cancer. (2) To facilitate the clinical translation of SPORE major projects. (3) To establish the Joint UAB/UMN Pancreatic Cancer Clinical Database (PCCD), as a caBIG compliant database which can then be linked to the Pancreatic Cancer Collaborative Registry (PCCR) at the University of Nebraska. (4) To provide and coordinate with the Tissue Resource and Molecular Pathology Core (Tissue Core) the acquisition of urine, serum, and tissue according to the existing clinical protocol and in support of SPORE projects. (5) To provide referring physicians, patients, and the public with information regarding pancreatic cancer research and clinical protocols available at UAB and UMN Comprehensive Cancer Centers, other Pancreatic SPORES, the national Pancreas Cancer Collaborative Registry (PCCR), and other Medical Centers via newsletter, web sites, and the Community Advocacy Board. (6) To provide the opportunity for minority Investigator inclusion and participation in clinical trial development through continued partnerships with the Morehouse School of Medicine and Tuskegee University, and with the assistance of the Facility for Access to Clinical Enrollment Services (FACES) of the UAB Comprehensive Cancer Center (CCC) and the National Center for Bioethics in Research and Healthcare at Tuskegee. The Core will be directed by Dr. Selwyn M. Vickers who will provide overall leadership and administration of the Core, along with the leadership of Co-Director Dr. C. Mel Wilcox, in coordination among its essential components including the UAB Multidisciplinary Gastrointestinal Oncology Clinic (MDGI) and the UMN Pancreas and Liver Center (PLC). In addition the Advocacy Sub-Core will play an integral role through involvement with the pancreatic cancer support group, patient and family education, and community awareness for pancreatic cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Alabama Birmingham
United States
Zip Code
Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129
Tiriac, Herve; Bucobo, Juan Carlos; Tzimas, Demetrios et al. (2018) Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. Gastrointest Endosc 87:1474-1480
Carlson, Marjorie; Watson, Adrienne L; Anderson, Leah et al. (2017) Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors. J Biomed Opt 22:1-9
Öhlund, Daniel; Handly-Santana, Abram; Biffi, Giulia et al. (2017) Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 214:579-596
Zhong, Yi; Macgregor-Das, Anne; Saunders, Tyler et al. (2017) Mutant p53 Together with TGF? Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. Clin Cancer Res 23:1607-1620
Contreras, Carlo M; Lin, Chee Paul; Oster, Robert A et al. (2017) Increased pancreatic cancer survival with greater lymph node retrieval in the National Cancer Data Base. Am J Surg 214:442-449
Roe, Jae-Seok; Hwang, Chang-Il; Somerville, Tim D D et al. (2017) Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell 170:875-888.e20
Chio, Iok In Christine; Tuveson, David A (2017) ROS in Cancer: The Burning Question. Trends Mol Med 23:411-429
Li, Yonghe; Oliver, Patsy G; Lu, Wenyan et al. (2017) SRI36160 is a specific inhibitor of Wnt/?-catenin signaling in human pancreatic and colorectal cancer cells. Cancer Lett 389:41-48
Feigin, Michael E; Garvin, Tyler; Bailey, Peter et al. (2017) Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nat Genet 49:825-833

Showing the most recent 10 out of 173 publications